2599792
Last Update Posted: 2016-05-02
Recruiting has ended
All Genders accepted | 18 Years-50 Years |
37 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656
Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and multiple-ascending doses of CTP-656 dosed for 7 days.
This two-part study will assess in healthy male and female subjects a solid oral dose formulation of CTP-656 vs. Kalydeco® and the safety, tolerability and pharmacokinetic profiles of escalating CTP-656 solid oral doses following 7 days of dosing. In Part B, three doses of CTP-656 ranging from 75 mg up to 300 mg per day will be studied.
Eligibility
Relevant conditions:
Healthy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov